Edgewise Therapeutics (EWTX) Accumulated Depreciation (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Accumulated Depreciation data on file, last reported at $7.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation rose 40.55% year-over-year to $7.3 million; the trailing twelve-month figure through Mar 2026 stood at $7.3 million (up 40.55% YoY), and the FY2025 full-year result was $6.8 million, up 44.48% from the prior year.
• Accumulated Depreciation advanced to $7.3 million in Q1 2026, from $6.8 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $7.3 million in Q1 2026 to a low of $785000.0 in Q1 2022.
• A 5-year average of $3.4 million and a median of $3.1 million in 2024 frame the typical range for Accumulated Depreciation.
• Across the five-year window, Accumulated Depreciation jumped 145.63% in 2023 and soared 40.55% in 2026, its largest moves.
• Tracing EWTX's Accumulated Depreciation over 5 years: stood at $1.1 million in 2022, then jumped by 145.63% to $2.6 million in 2023, then soared by 79.09% to $4.7 million in 2024, then soared by 44.48% to $6.8 million in 2025, then rose by 7.93% to $7.3 million in 2026.
• Business Quant data shows EWTX's Accumulated Depreciation at $7.3 million in Q1 2026, $6.8 million in Q4 2025, and $6.2 million in Q3 2025.